Search Results - "Weirather, Johannes"

Endothelial Actions of ANP Enhance Myocardial Inflammatory Infiltration in the Early Phase After Acute Infarction by Chen, Wen, Spitzl, Annett, Mathes, Denise, Nikolaev, Viacheslav O, Werner, Franziska, Weirather, Johannes, Špiranec, Katarina, Röck, Katharina, Fischer, Jens W, Kämmerer, Ulrike, Stegner, David, Baba, Hideo A, Hofmann, Ulrich, Frantz, Stefan, Kuhn, Michaela

“…RATIONALE:In patients after acute myocardial infarction (AMI), the initial extent of necrosis and inflammation determine clinical outcome. One early event in…”
Get full text

CD4+ Foxp3+ T-cells contribute to myocardial ischemia-reperfusion injury by Mathes, Denise, PhD, Weirather, Johannes, PhD, Nordbeck, Peter, MD, Arias-Loza, Anahi-Paula, PhD, Burkard, Matthias, Pachel, Christina, PhD, Kerkau, Thomas, MD, Beyersdorf, Niklas, MD, Frantz, Stefan, MD, Hofmann, Ulrich, MD

“…Abstract Objective The present study analyzed the effect of CD4+ Forkhead box protein 3 negative (Foxp3 − ) T-cells and Foxp3+ CD4+ T-cells on infarct size in…”
Get full text

Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma by Duell, Johannes, Maddocks, Kami J., González-Barca, Eva, Jurczak, Wojciech, Liberati, Anna Marina, De Vos, Sven, Nagy, Zsolt, Obr, Aleš, Gaidano, Gianluca, Abrisqueta, Pau, Kalakonda, Nagesh, André, Marc, Dreyling, Martin, Menne, Tobias, Tournilhac, Olivier, Augustin, Marinela, Rosenwald, Andreas, Dirnberger-Hertweck, Maren, Weirather, Johannes, Ambarkhane, Sumeet, Salles, Gilles

“…Tafasitamab (MOR208), an Fc-modified, humanized, anti-CD19 monoclonal antibody, combined with the immunomodulatory drug lenalidomide was clinically active with…”
Get full text

Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma by Duell, Johannes, Maddocks, Kami J., González-Barca, Eva, Jurczak, Wojciech, Liberati, Anna Marina, De Vos, Sven, Nagy, Zsolt, Obr, Aleš, Gaidano, Gianluca, Abrisqueta, Pau, Kalakonda, Nagesh, André, Marc, Dreyling, Martin, Menne, Tobias, Tournilhac, Olivier, Augustin, Marinela, Rosenwald, Andreas, Dirnberger-Hertweck, Maren, Weirather, Johannes, Ambarkhane, Sumeet, Salles, Gilles

Get full text

Activation of CD4+ T Lymphocytes Improves Wound Healing and Survival After Experimental Myocardial Infarction in Mice by HOFMANN, Ulrich, BEYERSDORF, Niklas, WEIRATHER, Johannes, PODOLSKAYA, Anna, BAUERSACHS, Johann, ERTL, George, KERKAU, Thomas, FRANTZ, Stefan

“…The role of adaptive immunity, especially CD4(+) T-helper cells, has not yet been systematically investigated in wound healing and remodeling after myocardial…”
Get full text

Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study by Salles, Gilles, Duell, Johannes, González Barca, Eva, Tournilhac, Olivier, Jurczak, Wojciech, Liberati, Anna Marina, Nagy, Zsolt, Obr, Aleš, Gaidano, Gianluca, André, Marc, Kalakonda, Nagesh, Dreyling, Martin, Weirather, Johannes, Dirnberger-Hertweck, Maren, Ambarkhane, Sumeet, Fingerle-Rowson, Günter, Maddocks, Kami

“…Patients with relapsed or refractory diffuse large B-cell lymphoma who are ineligible for autologous stem-cell transplantation have poor outcomes and few…”
Get full text

Myocardial aging as a T-cell–mediated phenomenon by Ramos, Gustavo Campos, van den Berg, Anne, Nunes-Silva, Vânia, Weirather, Johannes, Peters, Laura, Burkard, Matthias, Friedrich, Mike, Pinnecker, Jürgen, Abeßer, Marco, Heinze, Katrin G., Schuh, Kai, Beyersdorf, Niklas, Kerkau, Thomas, Demengeot, Jocelyne, Frantz, Stefan, Hofmann, Ulrich

“…In recent years, the myocardium has been rediscovered under the lenses of immunology, and lymphocytes have been implicated in the pathogenesis of…”
Get full text

Interleukin-13 deficiency aggravates healing and remodeling in male mice after experimental myocardial infarction by Hofmann, Ulrich, Knorr, Susanne, Vogel, Benjamin, Weirather, Johannes, Frey, Anna, Ertl, Georg, Frantz, Stefan

“…Activation of innate immunity, especially infiltration of monocytes, is critical for proper wound healing and scar formation after myocardial infarction (MI)…”
Get full text

Pharmacokinetics (PK) and pharmacodynamics (PD) in First-MIND: A phase Ib, open-label, randomized study of tafasitamab (tafa) ± lenalidomide (LEN) in addition to R-CHOP in patients (pts) with newly diagnosed diffuse large B-cell lymphoma (DLBCL) by Belada, David, Kopeckova, Katerina, Bergua Burgues, Juan Miguel, Stevens, Don A., Nowakowski, Grzegorz S., Waldron-Lynch, Maeve, Hadar, Nira, Weirather, Johannes, Lässig, Charlotte, Blair, Derek, Dreyling, Martin H.

“…e19553 Background: The combination of tafa + LEN has accelerated approval in the United States (2020) and conditional approval in Canada and Europe (2021) for…”
Get full text

Targeting P-Selectin by Gallium-68–Labeled Fucoidan Positron Emission Tomography for Noninvasive Characterization of Vulnerable Plaques: Correlation With In Vivo 17.6T MRI by Li, Xiang, Bauer, Wolfgang, Israel, Ina, Kreissl, Michael C, Weirather, Johannes, Richter, Dominik, Bauer, Elisabeth, Herold, Volker, Jakob, Peter, Buck, Andreas, Frantz, Stefan, Samnick, Samuel

“…OBJECTIVE—Nuclear imaging of active plaques still remains challenging. Advanced atherosclerotic plaques have a strong expression of P-selectin by the…”
Get full text

Role of CD4+ T-cells for regulating splenic myelopoiesis and monocyte differentiation after experimental myocardial infarction by Gladow, Nadine, Hollmann, Claudia, Weirather, Johannes, Ding, Xin, Burkard, Matthias, Uehlein, Sabrina, Bharti, Richa, Förstner, Konrad, Kerkau, Thomas, Beyersdorf, Niklas, Frantz, Stefan, Ramos, Gustavo, Hofmann, Ulrich

“…Myocardial infarction (MI) induces the generation of proinflammatory Ly6C high monocytes in the spleen and the recruitment of these cells to the myocardium…”
Get full text

Specific somatostatin receptor II expression in arterial plaque: (68)Ga-DOTATATE autoradiographic, immunohistochemical and flow cytometric studies in apoE-deficient mice by Li, Xiang, Bauer, Wolfgang, Kreissl, Michael C, Weirather, Johannes, Bauer, Elisabeth, Israel, Ina, Richter, Dominik, Riehl, Gabriele, Buck, Andreas, Samnick, Samuel

“…The rupture of atherosclerotic plaques is triggered by inflammation. Specific detection of inflammation is therefore the focus of many investigations…”
Get full text

MOR202, a Human Anti-CD38 Monoclonal Antibody, Mediates Potent Tumoricidal Activity In Vivo and Shows Synergistic Efficacy in Combination with Different Antineoplastic Compounds by Boxhammer, Rainer, Weirather, Johannes, Steidl, Stefan, Endell, Jan

“…Background: MOR202, a human anti-CD38 monoclonal antibody, is currently being evaluated in a phase I/IIa clinical trial for the treatment of multiple myeloma…”
Get full text

Long-term analyses from L-MIND, a phase II study of tafasitamab (MOR208) combined with lenalidomide (LEN) in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) by Düll, Johannes, Maddocks, Kami J., Gonzalez-Barca, Eva, Jurczak, Wojciech, Liberati, Anna Marina, Obr, Aleš, Gaidano, Gianluca, Abrisqueta, Pau, André, Marc, Dreyling, Martin H., Menne, Tobias, Dirnberger-Hertweck, Maren, Weirather, Johannes, Ambarkhane, Sumeet Vijay, Salles, Gilles A.

“…Abstract only 7513 Background: L-MIND (NCT02399085) is an ongoing, open-label, Phase II study of tafasitamab (MOR208), an Fc-modified, humanized, anti-CD19…”
Get full text

MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1–2a trial by Raab, Marc S, Engelhardt, Monika, Blank, Antje, Goldschmidt, Hartmut, Agis, Hermine, Blau, Igor W, Einsele, Hermann, Ferstl, Barbara, Schub, Natalie, Röllig, Christoph, Weisel, Katja, Winderlich, Mark, Griese, Janine, Härtle, Stefan, Weirather, Johannes, Jarutat, Tiantom, Peschel, Christian, Chatterjee, Manik

“…Treatment of multiple myeloma is not curative, but targeting CD38 improves patient survival. To further explore this therapeutic approach, we investigated the…”
Get full text

Efficacy of Tafasitamab (MOR208) Combined with Lenalidomide in Patients with High-Risk Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the L-Mind Study by González-Barca, Eva, Duell, Johannes, Cavallo, Federica, Sancho, Juan-Manuel, Nagy, Zsolt, Abrisqueta, Pau, Panizo, Carlos, Augustin, Marinela, Weirather, Johannes, Ambarkhane, Sumeet, Maddocks, Kami J., Kalakonda, Nagesh, Salles, Gilles

“…Introduction Patients with diffuse large B-cell lymphoma (DLBCL) that is refractory to primary immunochemotherapy are well recognized as a high-risk population…”
Get full text

Long-Term Subgroup Analyses from L-Mind, a Phase II Study of Tafasitamab (MOR208) Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma by Maddocks, Kami J., Duell, Johannes, González-Barca, Eva, Jurczak, Wojciech, Liberati, Anna Marina, de Vos, Sven, Nagy, Zsolt, Obr, Aleš, Gaidano, Gianluca, Abrisqueta, Pau, André, Marc, Dreyling, Martin, Menne, Tobias F, Dirnberger-Hertweck, Maren, Weirather, Johannes, Ambarkhane, Sumeet, Salles, Gilles

“…Introduction Patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT) have…”
Get full text

Poster: ABCL-022 Pharmacokinetics and Pharmacodynamics in First-MIND: A Phase Ib, Open-Label, Randomized Study of Tafasitamab ± Lenalidomide + R-CHOP in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma by Belada, David, Kopeckova, Katerina, Burgues, Juan Miguel Bergua, Stevens, Don, Nowakowski, Grzegorz S., Waldron-Lynch, Maeve, Hadar, Nira, Weirather, Johannes, Lässig, Charlotte, Blair, Derek, Dreyling, Martin

Get full text

ABCL-022 Pharmacokinetics and Pharmacodynamics in First-MIND: A Phase Ib, Open-Label, Randomized Study of Tafasitamab ± Lenalidomide + R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma by Belada, David, Kopeckova, Katerina, Burgues, Juan Miguel Bergua, Stevens, Don, Nowakowski, Grzegorz S., Waldron-Lynch, Maeve, Hadar, Nira, Weirather, Johannes, Lässig, Charlotte, Blair, Derek, Dreyling, Martin

Get full text

Tafasitamab combined with idelalisib or venetoclax in patients with CLL previously treated with a BTK inhibitor by Staber, Philipp Bernhard, Jurczak, Wojciech, Greil, Richard, Vucinic, Vladan, Middeke, Jan Moritz, Montillo, Marco, Munir, Talha, Neumeister, Peter, Schetelig, Johannes, Stilgenbauer, Stephan, Striebel, Frank, Dirnberger-Hertweck, Maren, Weirather, Johannes, Brugger, Wolfram, Kelemen, Peter, Wendtner, Clemens-Martin, Woyach, Jennifer Ann

“…Patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) whose treatment failed with a Bruton's tyrosine kinase inhibitor have poor outcomes…”
Get full text